Convalescent anti-SARS-CoV-2 MBT plasma

BIOLOGICAL2 trials

Sponsors

Instituto Grifols, S.A., Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

Conditions

COVID-19SARS-CoV-2 InfectionSafety and Efficacy

Phase 2

A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19)

CompletedNCT04547127

Instituto Grifols, S.A.COVID-19

Start: 2020-04-29End: 2021-02-04Updated: 2021-03-03

Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients

CompletedNCT04621123

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la CienciaSafety and Efficacy, SARS-CoV-2 Infection

Start: 2020-11-10End: 2021-07-28Updated: 2021-09-08

Related Papers

Patient and donor antibody profiles in early COVID-19 convalescent plasma therapy in the COnV-ert trial

Frontiers in Immunology2025-09-251 citations

Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients.

2022-05-1123 citations

High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial.

2022-02-0971 citations